Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

… Signs Vaccine Deal, And Sheds Penicillin

by Lisa M. Jarvis
December 6, 2010 | A version of this story appeared in Volume 88, Issue 49

GlaxoSmithKline is expanding its presence in emerging markets through a vaccines-manufacturing agreement with Moscow-based JSC Binnopharm. Under the deal, GSK will supply bulk vaccine and transfer fill-and-finish technology to enable Binnopharm to formulate the vaccines. Binnopharm will then sell GSK cervical cancer, rotavirus, and pneumococcal vaccines in the Russian market. Meanwhile, GSK is selling its penicillin plant in Bristol, Tenn., to Dr. Reddy’s Laboratories. The Indian drug firm also gains U.S. rights to the Augmentin and Amoxil antibiotic brands.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.